-
February 05, 2013
Bayer AG (BAYRY) recently presented results from two European phase III studies on ATX-101. ATX-101 is being ...
-
February 05, 2013
Ireland-based Shire plc (SHPG) recently announced that the company has reached an agreement in principle to resolve ...
-
February 04, 2013
Recently, GlaxoSmithKline (GSK) announced the initiation of a phase III study (COMBI-AD) to evaluate its oncology ...
-
February 04, 2013
Teva Pharmaceutical Industries Ltd. (TEVA) recently terminated its collaboration with CureTech Ltd. for the ...
-
February 04, 2013
AstraZeneca's (AZN) fourth-quarter 2012 core earnings of $1.56 per American Depositary Share (ADS) beat the Zacks ...
-
February 01, 2013
Roche Holdings Ltd. (RHHBY) recently reported 2012 results. Revenues grew 4% year over year to CHF 45.5 billion ...
-
February 01, 2013
Novo Nordisk (NVO) reported fourth quarter 2012 earnings of $1.83 per American Depository Receipt (ADR), up 21.2% ...
-
January 31, 2013
Alnylam Pharmaceuticals Inc. (ALNY) recently announced the publication of complete results from a phase I study on ...
-
January 31, 2013
Ryder System Inc. R), one of the world's largest providers of integrated logistics and transportation solutions, ...
-
January 30, 2013
Roche (RHHBY) announced that its wholly owned subsidiary, Genentech, has recently inked a global licensing agreement ...
-
January 25, 2013
GATX Corporation (GMT), a leader in leasing transportation assets, reported adjusted fourth quarter 2012 earnings of ...
-
January 25, 2013
Acorda Therapeutics, Inc. (ACOR) recently announced that it has been awarded a research contract worth $2.67 million ...
-
January 25, 2013
Novartis (NVS) recently announced that the US Food and Drug Administration (FDA) has approved Exjade (deferasirox) ...
-
January 25, 2013
Aircastle Limited (AYR) has delivered positive earnings surprises in the last four quarters with an average beat of ...
-
January 24, 2013
Teva Pharmaceutical Industries Ltd. (TEVA) recently announced disappointing top-line results from a study evaluating ...
-
January 24, 2013
The US Food and Drug Administration (FDA) recently approved Roche's (RHHBY) Avastin (bevacizumab) in combination ...
-
January 24, 2013
Swiss pharmaceutical giant Novartis (NVS) reported fourth quarter 2012 earnings per share of 84 cents, up 71% from ...
-
January 24, 2013
Bristol-Myers Squibb Company's (BMY) fourth quarter 2012 earnings (excluding special items) of 47 cents per share ...
-
January 23, 2013
Omeros Corporation (OMER) recently announced that it successfully completed the 90-day safety database lock for the ...
-
January 23, 2013
Abbott Labs (ABT) reported fourth quarter 2012 earnings of $1.51 per share, a penny ahead of the Zacks Consensus ...
